Background: SARS-CoV-2 vaccines are an invaluable resource against COVID-19. Current vaccine shortage makes it necessary to prioritize distribution to the most appropriate segments of the population. Methods: This is a prospective cohort study of 63 health care workers (HCWs) from a General Hospital. We compared antibody responses to two doses of BNT162b2 mRNA COVID-19 vaccine between HCWs with previous SARS-CoV-2 infection (experienced HCWs) and HCWs without previous infection (naïve HCWs). Findings: Seven days after the first vaccine dose, HCWs with previous infection experienced a 126-fold increase in antibody levels (p50 AU). After the second dose, no significant increase in antibody levels was found in experienced HCWs, whereas in naïv...
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has had a tremendous impac...
Background: Vaccine-induced population immunity is a key global strategy to control coronavirus dise...
Background: We present immunogenicity data 6 months after the first dose of BNT162b2 in correlation ...
In Italy, SARS-CoV-2 vaccination campaign prioritized healthcare workers (HCWs) to receive two doses...
SARS-CoV-2 vaccines are highly efficient against severe forms of the disease, hospitalization and de...
Background: Real-world population studies have shown waning immunity, over time, after receiving the...
Purpose: Clinical significance and durability of serological response after mRNA COVID-19 vaccines i...
Introduction: Data have suggested that SARS-CoV-2 infection causes an antibody response at least as ...
Background: To optimise the use of available SARS-CoV-2 vaccines, some advocate delaying second vacc...
Background: To optimise the use of available SARS-CoV-2 vaccines, some advocate delaying second vacc...
Introduction: Data have suggested that SARS-CoV-2 infection causes an antibody response at least as ...
Background: To optimise the use of available SARS-CoV-2 vaccines, some advocate delaying second vacc...
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has had a tremendous impac...
Background: To optimise the use of available SARS-CoV-2 vaccines, some advocate delaying second vacc...
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has had a tremendous impac...
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has had a tremendous impac...
Background: Vaccine-induced population immunity is a key global strategy to control coronavirus dise...
Background: We present immunogenicity data 6 months after the first dose of BNT162b2 in correlation ...
In Italy, SARS-CoV-2 vaccination campaign prioritized healthcare workers (HCWs) to receive two doses...
SARS-CoV-2 vaccines are highly efficient against severe forms of the disease, hospitalization and de...
Background: Real-world population studies have shown waning immunity, over time, after receiving the...
Purpose: Clinical significance and durability of serological response after mRNA COVID-19 vaccines i...
Introduction: Data have suggested that SARS-CoV-2 infection causes an antibody response at least as ...
Background: To optimise the use of available SARS-CoV-2 vaccines, some advocate delaying second vacc...
Background: To optimise the use of available SARS-CoV-2 vaccines, some advocate delaying second vacc...
Introduction: Data have suggested that SARS-CoV-2 infection causes an antibody response at least as ...
Background: To optimise the use of available SARS-CoV-2 vaccines, some advocate delaying second vacc...
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has had a tremendous impac...
Background: To optimise the use of available SARS-CoV-2 vaccines, some advocate delaying second vacc...
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has had a tremendous impac...
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has had a tremendous impac...
Background: Vaccine-induced population immunity is a key global strategy to control coronavirus dise...
Background: We present immunogenicity data 6 months after the first dose of BNT162b2 in correlation ...